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Mesenchymal stromal-cell transplants induce
oligodendrocyte progenitor migration and
remyelination in a chronic demyelination model
J Jaramillo-Mercha´n1, J Jones1, JL Ivorra2, D Pastor3, MC Viso-Leo´n1, JA Armengo´l4, MD Molto´2,
E Geijo-Barrientos1 and S Martı´nez*,1
Demyelinating disorders such as leukodystrophies and multiple sclerosis are neurodegenerative diseases characterized by the
progressive loss of myelin that may lead toward a chronic demyelination of the brain’s white matter, impairing normal axonal
conduction velocity and ultimately causing neurodegeneration. Current treatments modifying the pathological mechanisms are
capable of ameliorating the disease; however, frequently, these therapies are not sufficient to repress the progressive
demyelination into a chronic condition and permanent loss of function. To this end, we analyzed the effect that bone marrow-
derived mesenchymal stromal cell (BM-MSC) grafts exert in a chronically demyelinated mouse brain. As a result,
oligodendrocyte progenitors were recruited surrounding the graft due to the expression of various trophic signals by the grafted
MSCs. Although there was no significant reaction in the non-grafted side, in the grafted regions oligodendrocyte progenitors
were detected. These progenitors were derived from the nearby tissue as well as from the neurogenic niches, including the
subependymal zone and dentate gyrus. Once near the graft site, the cells matured to myelinating oligodendrocytes. Finally,
electrophysiological studies demonstrated that axonal conduction velocity was significantly increased in the grafted side of the
fimbria. In conclusion, we demonstrate here that in chronic demyelinated white matter, BM-MSC transplantation activates
oligodendrocyte progenitors and induces remyelination in the tissue surrounding the stem cell graft.
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Demyelinating disorders are a group of diseases characte-
rized by myelin loss. The cause for this destruction is varied,
such as an autoimmune attack (i.e., multiple sclerosis (MS))1,2
or metabolic/genetic alterations (leukodystrophy).3 The
loss of myelin ultimately causes neuronal disruption, as the
oligodendrocytes are crucial for both the metabolic support of
the axons4 as well as the correct transmission of the nerve
impulse.
Oligodendrocyte progenitor cells (OPCs), which express
the NG2 proteoglycan,5 can be detected migrating and
differentiating into mature oligodendrocytes as early as 7
days after a demyelinating lesion.6 These cells are extensively
distributed in the central nervous system (CNS), are capable
of dividing throughout the lifespan and are activated when
there is a demyelinating process.7
MS can be divided into two main stages: acute and chronic.
Although in the acute phase the nearby OPCs are capable of
remyelinating the damaged axons,8–10 in the chronic phase
the cell’s migratory and differentiating capabilities are altered,
resulting in sustained and progressive demyelination.11 This
is at least partly because of the lack of factors that recruit and
stimulate remyelinating properties of OPCs.12 Thus, the
objective of this work was to develop a remyelinating therapy
in chronically demyelinated white matter based on activation
of existing OPCs to induce migration and differentiation.
To this end, there are a number of studies concerning
trophic-based activation of OPCs (reviewed by Rivera
et al.13). Many of the identified trophic factors are known to
be produced and secreted by bone marrow-derived mesench-
ymal stromal cells (BM-MSCs). Previous reports have proven
that these cells are capable of inducing regeneration,
neuroprotection and functional recovery in an MS mouse
model.14–16 Though the cause for this effect in vivo is not well
understood, there is evidence in vitro that BM-MSCs are
capable of stimulating the proliferation and differentiation
of neural progenitors toward an oligodendrocyte lineage.17,18
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Here we describe the use of BM-MSC in a model of chronic
demyelination. This approach will give us insight as to the
mechanisms by which BM-MSCs may activate OPCs in vivo,
and ultimately induce remyelination and axonal conduction
improvement.
Results
MSCs activate oligodendrogenesis and remyelination.
After 12 weeks of cuprizone-embedded diet, the mice
presented clear demyelinating lesions in the corpus callosum
(CC) and fimbria (Figures 1b–d). However, although in the
CC both myelinated and non-myelinated patches were
detected (Figure 1c), the fimbria was rather homogeneously
non-myelinated (Figure 1d). Thus, the surgical procedures
were decided to be performed in this white matter structure.
As early as 2 weeks after stereotaxic-guided intra-fimbrial
transplantation (Figure 2a), NG2-positive OPCs as well as
mature oligodendrocytes (myelin basic protein (MBPþ ))
were detected surrounding the grafted cells (Figures 2b–d).
The percentage of NG2, MBP and glial fibrillary acidic protein
(GFAP) immunoreactivity was calculated and compared in the
sham controls and stem cell-treated groups (Figures 2e–h).
Concerning NG2, there was a slight increase in expression in
the sham-treated group compared with its contralateral side,
although not as remarkable as that observed in the stem cell-
treated group, where over 10 times more NG2 was detected
(Figures 2e and f). This was also observed in both MBP and
GFAP staining, where the stem cell-injected fimbria presented
higher levels of expression of these myelin and astrocyte
markers, respectively, compared with the contralateral side
(Figures 2e, g and h). The sham-treated fimbria did not differ
Figure 1 Effect of chronic intake of cuprizone in the CNS. (a) Chronogram of the experimental protocol. (b) Schematic representation of a transveral section of the brain,
indicating with red squares the CC (c) and fimbria (d). (c) Immunohistochemistry of a transveral section of the CC of a mouse treated for 3 months with cuprizone and stained
for MBP (in green). Arrows indicate patches of demyelination (MBP-negative), similar to that seen in chronic lesions of MS. (d) Proteolipid protein (PLP) (red) and MBP
(green) staining in the fimbria of a non-treated mouse and of a cuprizone-treated mouse of the same age. Note the lack of expression of the two myelin-forming proteins,
indicating a homogenous demyelination process of the fimbria. Scale bar, 75 mm (c and d)
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with its contralateral side in MBP staining, whereas for GFAP
a slight increase was detected.
The results shown here indicate that there was a significant
increase in OPCs and mature oligodendrocytes in the fimbria
treated with MSCs, which in turn gave rise to newly formed
myelin.
MSC transplantation increases the conduction velocity
of demyelinated fibers. Axon conduction velocity was
measured in order to confirm if the newly formed myelin
around the MSC graft was functional (Figures 3a–d). In the
recordings obtained with electrodes placed in the vicinity of
the graft (see Materials and Methods), we detected two
different populations of axons corresponding to fast- and
slow-conducting axons (Figure 3e); in normal mice the
average conduction velocity of these components was close
to 1 and 0.4 m/s, respectively (measured at room tempera-
ture). The slow conduction fibers were absent when the
region of the fimbria near the hippocampus was registered
(Figure 3f).
The values of conduction velocity of fast-conduction fibers
are given in Figure 3g. In normal (wild type), control
demyelinated and sham-operated animals, the conduction
velocity of the fast and slow (not shown) fibers was similar in
all the regions tested (only rostral and caudal registered
regions are shown). However, in stem cell-treated mice the
conduction velocity of the fast fibers was almost twice as fast
in the rostral region compared with the other groups (t¼ 3.11;
P-value¼ 0.032), although the caudal region had increased
values, though not statistically significant. The conduction
velocity of the slow fibers did not change in any experimental
condition (data not shown).
Thus, our electrophysiological analysis indicated that MSC
transplants increased axon conduction speed of the area in
the fimbria surrounding the graft. This effect is higher in the
anterior region of the fimbria, which represents the axonal
segments localized closer to the caudal subependymal zone
(cSEZ) in relation to the graft.
MSCs activate oligodendrocyte progenitors by releasing
trophic factors. As commented in the Introduction section,
several authors have indicated that MSCs are capable of
releasing a number of trophic factors that activate OPCs and
induce their differentiation toward myelinating oligodendro-
cytes. Several factors that are known to induce this effect in
OPCs were analyzed in MSCs both in vitro (before transplan-
tation, Figure 4a) and in vivo (Figure 4b). As a result,
neurotrophic factor-4/5 (NT4/5), neurotophic factor-3 (NT3),
platelet-derived growth factor (PDGF) and nerve growth
factor-b (NGF-b) were detected both in vitro and in vivo. The
contralateral (control) fimbria did not show any significant
immunoreactivity of any of the factors analyzed. There was no
immunoreactivity detected for these trophic factors in the
sham group (data not shown). The combinations of several of
these growth factors have been previously shown to be
capable of inducing remyelination in cuprizone-treated mice.19
As no transdifferentiation or cell fusion processes were
observed (data not shown), we conclude that the activation of
native OPCs and oligodendrocytes was due to the release of
at least these trophic factors by the grafted stem cells.
MSCs stimulate oligodendroglial differentiation and
migration of cells from the SEZ and dentate gyrus of
the hippocampus. The results shown so far indicate an
activation of OPCs in the fimbria due to the paracrine effect
of several trophic factors from the grafted MSCs. However,
this increase in OPCs derives not only of nearby areas
surrounding the fimbria, but possibly from the neurogenic
niches, the SEZ and the dentate gyrus (DG) of the
hippocampus. This phenomenon is possible because of the
fact that the ventricular surface of the CC, caudal septum and
fimbria coincide in the dorso-caudal pole of the lateral
ventricle (LV), which advances over the ventricular surface
of the hippocampal formation.
In the case of the SEZ, a number of NG2-positive cells were
detected migrating from this region in the side of the fimbria
where the stem cells were injected (Figure 5a). These cells
presented cytoplasmic prolongations with a rostro-medial to
caudo-lateral orientation and followed the SEZ of the right LV,
with practically no invasion of the alveus or outer cortical
hippocampal structures (Figures 5b–f).
To further confirm if the NG2-positive cells detected from
the SEZ toward the fimbria originated in this area, Nilo1
expression was analyzed (Figure 5g). This marker is specific
for neural precursors of the SEZ.20 As a result, the vast
majority of the NG2-positive cells also expressed Nilo1,
confirming that they derive from the SEZ (cells in purple).
Migrating NG2þ cells were not detected in the contralateral
side of the fimbria, where no stem cells were injected (Figures
5h and i).
Also, the subgranular layer of the DG was analyzed in
longitudinal sections, as this neurogenic area is relatively
close to the grafted site (Figures 6a and b). Stronger MBP
immunostaining was detected in the rostral fimbria near the
DG with respect to more caudal areas of the fimbria (Figures
6c and d). Also, some cells seemed to detach from the distal
pole of DG subgranular and migrated through the subepial
region (Figures 6e–g), to finally invade the nearby fimbria
parenchyma and even extend prolongations that surrounded
the axons, similar to that observed in mature oligodendrocytes
(Figures 6h–j). These NG2þ cells from the subgranular zone
of the DG were Nilo1-negative (data not shown).
Discussion
In this work, we analyzed the effect that MSC grafts have in
a chronic demyelinated model. As a result, OPCs, identified as
NG2þ cells, increased in number and migrated from the
nearby neurogenic niches toward the graft, which include cells
from the subependymal (NG2þ /Niloþ ) and subgranular
(NG2þ /Nilo ) zones (Figure 7). Furthermore, these pro-
genitor cells matured into oligodendrocytes and remyelinated
the surrounding area. This seemed to be due to the effect of
various trophic factors secreted by the grafted MSCs, inducing
OPC migration toward demyelinated white matter and
differentiation to ultimately promote remyelination.
Toxicity-induced demyelinating models such as cuprizone
are similar to the lesions that appear in MS, with massive
apoptosis of oligodendrocytes; however, if the treatment is
prematurely suspended, spontaneous remyelination occurs.
This physiological remyelination occurs in two phases:
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(A) OPC proliferation and colonization of the demyelinated
area and (B) differentiation toward immature oligodendro-
cytes that contact with demyelinated axons, followed by OPC
maturation and remyelination. This process is regulated by a
complex mechanism of coordinated expression of signaling
factors (reviewed by Chari et al.8,9).
OPCs are normally generated in the SEZ and DG of the
hippocampus in adult animals. During development, OPCs
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originate and migrate from the embryonic subventricular zone
into the forebrain parenchyma.7 Caudally, these precursors
migrate into the fimbria and hippocampus. Therefore, the
fimbria represents an ideal area of interest to explore
remyelination because of its localized source of OPCs from
the cSEZ.
OPCs are constitutively present in the adult CNS and can
specifically differentiate in vivo toward remyelinating oligo-
dendrocytes. However, in some myelin diseases, such as in
the primary progressive and evolution of relapsing-remitting
MS, there is a multiple dysfunction in the remyelinating
mechanisms that characterize the appearance of chronic
lesions,21 similar to that observed in chronic cuprizone-treated
mice.22 This may be because of either an absence of nearby
OPCs or that they are quiescent and do not react to the signals
that normally appear during the early stages of demyelination.
In both cases, they may be due to, at least partly, the lack of
factors that activate the necessary mechanisms to induce
regeneration. Thus, it is of great importance to stimulate the
quiescent OPCs, as well as induce their migration to the
affected area.
There are numerous growth factors known to induce
remyelination, including PDGF,23 fibroblast growth factors
(FGFs),24 NT325 and insulin-like growth factor (IGF)-1.26,27
Also, certain combinations of growth factors work synergis-
tically to repair and remyelinate. For example, FGF2 along
with IGF activate OPCs,28 whereas PDGF convert adult
OPCs, which divide slowly, to ‘newborn’ progenitors with a
higher proliferation rate.29
However, there are certain disadvantages in using trophic
factors alone as a possible treatment. One of the most
important disadvantages is to find the proper dosage. An
insufficient amount of the trophic factor would not have any
effect on the remyelination process, but an excess may
actually cause further damage. This was observed, for
example, with brain-derived neurotrophic factor (BDNF)
infusion after an axotomy in rats.30 In this work, high doses
of the trophic factor inhibited motorneuron axonal regenera-
tion. At the clinical level, ALS patients were administered
intrathecally different doses of BDNF, causing an overall
worsening compared with placebo.31 This cited article also
shows another possible problem with growth factor treatment:
the method of administration. Although oral intake may cause
little to no effect on the tissue of interest, especially because
many growth factors are not capable of surpassing the blood–
brain barrier, direct injection or using micro-pumps has shown
that the necessary concentration of the trophic factor to induce
regeneration or neuroprotection may cause side effects that
surpass the possible benefits. For example, NGF infusion in
Alzheimer’s disease patients resulted in a very slight cognitive
amelioration but accompanied by constant back pain that only
disappeared when the treatment was halted.32 In addition,
GDNF intraventricular delivery has been used in Parkinson’s
disease, which resulted in no clinical benefits and unwanted
side effects.33 The importance of adverse events demonstrate
the biological activity of neurotrophic factors in human’s
neurodegenerative conditions and reveal the importance of
adequate delivery pattern (continuous instead of intermittent)
close to neuronal targets in physiological concentrations.
MSCs, on the other hand, are known to secrete a large
array of factors.34 These factors are released in an autocrine
and paracrine way in response to the niche they are placed, in
order to regenerate or protect nearby degenerating tissue. In
MS, MSC transplantation presents an additional benefit,
which resides in the modulation and suppression of the
immunological response that characterizes this disease by
inhibiting and regulating T-cell proliferation, as well as
suppresses the inflammatory response.35
Some of the factors that MSCs release are known to
promote the differentiation of neural progenitor cells toward
oligodendrocytes,36 establishing an oligodendrocytic niche.
We describe the expression of an array of growth factors.
These trophic factors released by the MSC reach the
neurogenic niches to promote OPC recruitment toward the
source releasing them. These OPCs are active as they
express NG2 and migrate from the caudal pole of the LV SEZ
homolateral to the transplant. This stream of cells continues
up to the graft, without abandoning the subependymal niche.
Also, some OPCs from the DG of the hippocampus were
observed.
Interestingly, in our sham controls we observed a slight
increase in OPCs around the injection site. A previous study
described that OPCs are activated when there is an ischemia,
demyelination or other lesion in the CNS.37 However, these
OPCs were not capable of differentiating into mature
oligodendrocytes nor initiate any reactive myelin formation,
demonstrated by the absence of MBP immunoreaction.
Even though we observe the activation and maturation of
OPCs in a chronic demyelinated tract, it is necessary to
confirm that functional remyelination occurs. In chronic
lesions of MS, the oligodendrocytes that survive in a
demyelinating lesion and have lost their myelinating expan-
sions are not capable of contributing to the remyelination,
despite being capable of forming new myelin layers, because
they cannot place these layers in the demyelinated axons
(reviewed by Franklin38). Thus, it is necessary to perform
electrophysiological studies in order to confirm that the
remyelination process observed here results in a functional
recovery. In this work, we measured the conduction velocity of
several areas in the periphery of the transplant. Under normal
Figure 2 OPCs around the graft site. (a) Diagram depicting the location of the injection site. The fimbria (Fi) is adjacent to the CC and the hippocampus, subdivided into
CA1, CA2 and CA3. (b) MSC-grafted fimbria immunostained for H2d (green) and NG2 (red) in the injection site. In all cases, the graft stimulated OPC clustering. (c) Stem
cell-treated fimbria immunostained for GFP (green) and MBP (red) in the injection site. (d) Close-up image of a region of the periphery of the graft (inset in c) staining for MBP
(red) and GFP (green) where the stem cells can be seen intertwined with myelinated fibers. (e) NG2, MBP and GFAP expression (in red) in the fimbria of mesenchymal stem
cell-grafted mice, sham-operated and the control demyelinated fimbria of the grafted mice. Note that the NG2 in MSC was taken 1mm rostrally from the graft where no MSC
were present. (f–h) Quantification of the expression of NG2 (f), MBP (g) and GFAP (h) in the fimbria of MSC-grafted mice (green bars), sham-operated (yellow bars) and the
control fimbria (blue bars) of both groups. A significant increase of the NG2 expression (t¼  3.19; P-value¼ 0.013), MBP expression (t¼  4.34; P-value¼ 0.004) and
GFAP expression (t¼  2.60; P-value¼ 0.032) was detected in the MSC-grafted mice compared with the sham-operated mice, whereas no significant differences were
detected in both control demyelinated fimbria (corresponding to the contralateral side of the fimbria) in sham-operated and control demyelinated fimbria in MSC-grafted.
Scale bar, 100 mm
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Figure 3 Axon conduction velocity in various regions of the fimbria. (a and b) Images of the extracted fimbria, depicting the location of the graft. (c) The stimulus electrode
located in the caudal region (c) of the fimbria and a registry electrode in the rostral area (caudal to the graft) (r). (d) Details of the position of the two registry electrodes to obtain
the recordings of the caudal fibers around the graft (white line). (e and f) Two fibers were detected: fast (thicker myelin sheaths) and slow (thin and/or non-myelin sheaths)
fibers. (g) Histogram depicting the axon potential velocities in the fast fibers measured in the MSC (green), normal non-demyelinated (black), sham-operated (yellow) and
control demyelinated fimbria (blue) in the rostral (R) or caudal (C) regions. Red line denotes wild-type values. Scale bar, 1 mm (a and b); 500mm (c); and 100mm (d)
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circumstances, two fiber types can be detected: fast and slow
fibers, corresponding to axons with thick and thin myelin
sheaths, respectively. Interestingly, in our model after
demyelination the conduction velocities of both fast and slow
fibers were not severely affected compared with normal
values. This was possibly due to the spontaneous compen-
satory mechanisms in the axon, such as axonal dilatation that
increases axonal diameter. In the MSC-treated group, the
conduction velocity of the fast fibers doubled with respect to
the other groups, including wild-type controls. Also, when the
rostro-medial area of the fimbria was registered, close to
the fornix, we observed a very significant increase in the
conduction velocity, possibly due to the proximity of OPC
migratory routes deriving from the neurogenic niches. In this
area a large concentration of OPCs was observed. This strong
increase of impulse transmission could be due to the
remyelination of dilated axons, which could restore saltatory
conduction in already dilated axons.
In conclusion, MSC transplantation resulted in the activa-
tion of nearby oligodendrocyte progenitors, which because of
the cuprizone treatment maintained an unactivated state.
In turn, these OPCs matured into myelinating oligodendrocytes.
This was due to the secretion of several trophic factors, which
also activated the neurogenic niches, provoking the migration
of OPCs from the subventricular zone and DG of the
hippocampus toward the graft. These results indicate a
possible stem cell-based therapy where mesenchymal stem
cells may be delivered into the CNS of MS in the chronic phase
of the lesions.
Materials and Methods
Animals. All experiments have been performed in compliance with the Spanish
and European Union laws on animal care in experimentation (Council Directive
86/609/EEC) and have been analyzed and approved by the Animal
Experimentation Committee of our University. Green fluorescent protein (GFP)
(C57Bl/6-Tg(ACTB-EGFP)1Osb/J) transgenic mice were used as donors, whereas
C3H/He (H2Kk) mice were used as hosts. Both animal strains were bred and
maintained in our animal facilities.
Demyelinating treatment. Four-week old C3H/He mice were given a diet
with 0.2% cuprizone (w/w) for 12 weeks ad libitum in order to obtain a chronic
version of toxicity-induced demyelination, as previously indicated,39 but with the
following changes. Finely powdered cuprizone (Sigma-Aldrich, St. Louis, MO,
USA) was dissolved in 60% tap water (w/v) with 0.5% (w/v) commercialized cane
sugar. The cane sugar was added to avoid the weight loss observed in other
studies because of the cuprizone treatment. After 12 weeks, the mice were grafted
with MSCs (or culture medium in the case of sham-operated group) and returned
to normal diet until their death, which was depending on the test at 15 or 90 days
(see timeline in Figure 1a).
Isolation and culture of MSCs. The isolation and culture of MSCs was
performed as in our previous studies.40,41 Briefly, the bone marrows of transgenic
GFP mice were extracted, disaggregated and cultured in plastic flasks. The
following culture medium was used: high-glucose Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen, Life Technologies, Paisley, UK), 15% fetal bovine
serum (Biochrom AG, Berlin, Germany) and 1% penicillin/streptomycin (Sigma-
Aldrich). The stem cells were maintained for 3–4 weeks (passages 2–3) before
proceeding to the surgical interventions.
Cell transplantation and experimental groups. A total of 24 mice
were injected with MSCs (n¼ 10 for immunohistochemistry, n¼ 8 for
electrophysiology and n¼ 6 for electron microscopy). Also, for the sham-operated
group, another 10 animals were used (n¼ 4 for immunohistochemistry, n¼ 3 for
electrophysiology and n¼ 3 for electron microscopy). In both groups, before
performing the surgical procedure, 0.1 mg/kg of buprenorphine (Buprex, Schering-
Plough, Madrid, Spain) was injected into the mice. Isoflurane (Esteve Veterinary,
Milan, Italy), an inhalational anesthesia, was used, and the mice was placed on a
stereotaxic apparatus (Stoelting, Wheat Lane Wood Dale, IN, USA). The animal
was monitored, and anesthesia concentration was controlled. The injections were
performed in the right fimbria at the following stereotaxic coordinates (Kopf, model
900 small animal stereotaxic instrument; anteroposterior relative to bregma,
mediolateral and dorsoventral from the surface of the brain):  0.11,  0.16
and  0.26mm, respectively. The MSCs were injected using a 5 ml Hamilton
syringe (Reno, NV, USA) coupled with a DMEM-rinsed siliconed-capillary glass.
In the MSC-operated group, 300 000 cells were transplanted in 2ml of DMEM.
The left fimbria was considered as the internal control of demyelination for all
experimental groups and in all studies except in electron microscopy, where
the side of the graft was randomized. After the injection, the incision was sutured
and the mice were monitored throughout the whole process of experimentation.
For the immunohistochemical analysis, the mice were killed at 15 days after
the surgical intervention. As for the remaining tests (quantitative PCR,
electrophysiology and electron microscopy), the mice were killed 3 months after
the intervention.
Figure 4 Trophic factor expression after grafting. (a) PCR analysis of cultured mesenchymals stromal cells. (b) Immunohistochemical analysis of the stem cell-treated
fimbria for the expression of various trophic factors compared with the control fimbria. NT4/5, NT3, PDGF and NGF-b were expressed in MSC-grafted fimbria. The histogram to
the right depicts the quantification of the immunoreactivity of the trophic factors analyzed by immunohistochemistry, relative to the contralateral (non-treated) side of the
fimbria. A value over 1 indicates a higher immunoreactivity in the treated side of the fimbria compared with the non-treated side. Scale bar, 50 mm
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Immunofluorescence technique. To fixate the brain tissue, the mice
were anesthesized using isoflurane and perfused intracardially 4% filtered
paraformaldehyde (PFA) in phosphate buffer (PB; pH 7.4). The brain was carefully
excised and kept in 4% PFA overnight. After fixation, the samples were
cryoprotected for 12 h at 4 1C in 15% sucrose, followed by incubation overnight in
30% sucrose. Finally, samples were embedded in Neg-50 Frozen Section Medium
(Richard-Allan Scientific, Kalamazoo, MI, USA). Twelve micrometer transverse or
longitudinal serial sections were obtained using a Microm HM525 cryostat and
mounted on seven parallel series and processed for immunohistochemistry
(Microm, Walldorf, Germany). Double-labeled immunohistochemistry was
performed using the following primary antibodies: rabbit anti-NG2 (1 : 150; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-MBP (1 : 100; Oncogene
Research Products, La Jolla, CA, USA), rat anti-proteolipid protein (AA3-PLP)
(1 : 50; Millipore, Billerica, MA, USA), sheep anti-NT3 (1 : 200; Abcam, Cambridge,
UK), sheep anti-NT4/5 (1 : 200; Chemicon, Millipore, Oxford, UK), sheep anti-NGF-
b (1 : 500; Chemicon), goat anti-platelet-derived growth factor (PDGF) (1 : 200;
Santa Cruz Biotechnology), hamster anti-Nilo1,20 mouse anti-H2Db haplotype
(1 : 100; BD Pharmingen, San Jose, CA, USA), mouse monoclonal anti-GFP
(1 : 200, Molecular Probes, Grand Island, NY, USA) and rabbit polyclonal anti-GFP
(1 : 500, Molecular Probes). Even though the grafted stem cells express GFP,
immunostaining was performed on this protein in order to amplify the signal,
facilitating its observation. As secondary antibodies, for GFP we used anti-mouse
or anti-rabbit Alexa Fluor 488 (1 : 500; Molecular Probes). In the rest of cases,
either Alexa Fluor 594 (1 : 500; Molecular Probes) or biotinylated secondary
antibodies were used (1 : 200; Vector Laboratories, Peterborough, UK) followed by
an incubation with streptavidin conjugated with Texas Red or aminomethyl
coumarin acetate (1 : 500; Vector Laboratories). 40,6-Diamidino-2-phenylindole
(2mg/ml; Molecular Probes) was used to stain nuclei. For the expression of NT3,
NT4/5, NGF-b and PDGF, immunostaining with 3,30-diaminobenzidine (Appli-
chem, Darmstadt, Germany) was performed. Controls of immunostaining were
performed in two slides of each sample following the same procedure, but
eliminating primary or secondary antibodies. Histological samples were observed
under a fluorescence microscope (Leica DM6000D; Leica Microsystems, Wetzlar,
Germany). Micrographs were taken with DFC350/FX and DC500 Leica cameras.
Electrophysiological experiments. The recordings were performed in a
preparation of the fimbria–hippocampus ‘in vitro’ prepared from non-treated, MSC-
injected and sham groups, as well as their internal controls. The animals were
killed by cervical dislocation at 3 months after grafting or the equivalent age for
sham-treated and controls, and the fimbria–hippocampus complex was dissected
and placed in a submersion type recording chamber and superfused with
extracellular solution (composition in mM: NaCl, 124; KCl, 2.5; NaH2PO4, 1.25;
Figure 5 Analysis of the neurogenic niches: subventricular zone. (a–f) Coronary sections of the LV showing NG2þ cells migrating from the subventricular zone to the
MSC-grafted fimbria. NG2þ cells, corresponding to OPCs, migrate rostro-caudally from the subventricular zone in the side of the fimbria where the stem cells were injected (a).
The cells migrated bordering the lateral ventricular until they reached the fimbria (b–f). (b) Immunohistochemical image depicting the NG2þ cells bordering the LV.
(c) Close-up of inset in b, where the cells can be seen with a migratory morphology. (d) NG2þ cells entering the fimbria. (e) Close-up of the inset in d. (f) NG2þ cells surrounding
the stem cell graft. The scheme to the right shows the spatial distribution of the images observed in a–f. g, graft; Fi; fimbria; lv, lateral ventricle; Hi, hippocampus.
(g) Immunohistochemical analysis of the migrating NG2þ /Nilo1þ cells. In the image, H2d is in green (Alexa Fluor 488), NG2 in red (Texas Red), Nilo1 is light blue
(aminomethyl coumarin acetate) and 40,6-diamidino-2-phenylindole in dark blue. Double-positive NG2 and Nilo1 cells are detected in purple. (h–i) The contralateral side
of the fimbria, where no cells were injected, did not present the migrating cells observed in the treated side. Scale bar, 100mm (c and h); 75mm (e); 50mm (a, b, d, f and i);
and 25mm (g)
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NaHCO3, 26; CaCl2, 2; MgCl2, 1; glucose, 10; and osmolarity 300mOsm/kg
(pH 7.4), when saturated with 5% CO2þ 95% O2). The recordings were obtained
at room temperature (24.3–26.3 1C). The fimbria was stimulated at the caudo-lateral
end with a concentric bipolar electrode (Frederick Haer & Co, Bowdoin, ME, USA)
using pulses of 0.1 ms of duration. Two simultaneous extracellular recordings were
obtained with glass pipettes (0.2–5MO) filled with extracellular solution; the two
electrodes were placed in parallel with the fimbria axons in different places with
respect to the graft. In the grafted fimbria, the graft was identified because of its
Figure 6 Analysis of neurogenic niches: DG. (a and b) Horizontal sections of the contralateral (non-treated) and MSC-grafted side of the fimbria, respectively, showing the
tight location of the DG and fimbria, delimited by yellow-dotted lines. Blue is 40,6-diamidino-2-phenylindole staining. (c and d) MBP staining, in red, of the rostral (c) (see ‘r’
yellow line in the localization scheme) and caudal (d) regions (see ‘c’ yellow line in the localization scheme) to the graft (see ‘g’ green line in the localization scheme), showing
that the area closest to the DG expresses more MBP. (e) Reconstructed semi-thin ultramicrotome sagittal section showing cells migrating from the DG to the fimbria. (f–h) High
magnifications of insets in e. Red arrows in f and g indicate cell polarity according to a possible cell migration from the DG. Red arrowheads in h indicates cytoplasmic
prolongations from a oligodendrocyte ensheathing various axons. (i and j) Oligodendrocyte precursors migrating toward the graft, as observed by electron microscopy. Scale
bar, 100 mm (a and b); 50mm (c–e); 10mm (f and g); and 5 mm (h)
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native GFP staining, whereas in the sham-operated group the injection site could
be detected because of the visible slight scar. The two recording electrodes were
placed in four zones located rostro-medial, caudo-lateral, parallel and inside, with
respect to the graft (in MSC group); in the sham group or internal control group,
we used equivalent recording positions. The conduction velocity was measured
from the distance between the tips of both electrodes and the difference in the
latency of the propagated action potential.
Transmission electron microscopy (TEM) studies. For TEM, the
mice were perfused with 2% PFA /1.5% glutaraldehyde in PB 0.12M with Cl2Ca.
Brains were post-fixed in the same fixative overnight at 4 1C, and fimbria was
dissected and washed for 12 h in PB 0.1M (pH 7.4) with 7% sucrose. Afterwards,
the fimbria were post-fixed in 1% osmium tetraoxide in 0.2 M cacodilate buffer,
rinsed and stained with 2.5% uranile acetate in Michaelis buffer. Samples were
dehydrated with acetone and propylene oxide and embedded in EPON. Thick
sections (1 mm) were obtained rostro-medially, caudo-laterally and at the level of
the graft. Ultra-thin electron miscroscope images were observed by the EM
department in the University of Murcia, Spain.
Quantification of immunoreactivity in the fimbria. The quantifica-
tion of GFAP, MBP and NG2 immunoreactivity in the fimbria was performed using
imaging analysis software (ImageJ). To do so, one image was taken of the whole
fimbria per serial section (one out of every seven consecutive sections) and
changed to an 8-bit image (becoming a black and white image). Then, the fimbria
was delimited and the percentage of illuminated pixels (white pixels) was
calculated, following the instructions published in Hartig.42 Finally, the average and
S.D. of the seven percentages were calculated. This was performed both in the
sham-operated and stem cell-treated groups and compared. In the case of the
expression of the trophic factors analyzed in the fimbria, these were quantified in a
similar fashion, only that they were normalized to the contralateral (non-treated)
side of the fimbria. In this manner, a value over 1 indicated that the treated side
presented higher immunoreactivity compared with the non-treated side.
PCR analysis. Cultured MSCs were analyzed for gene expression of
neurotrophic factors NT3, NT4/5, PDGF and NGF-b. Total RNA was extracted
using the RNeasy mini kit (Qiagen, Venlo, Netherlands) and DNase I treatment to
avoid genomic contamination. Reverse Transcription was performed using the
Quantitect Reverse Transcription kit (Qiagen) and processed using the Qiagen
Multiplex PCR kit. The sequences of the primers used were: NT3 forward
50-AGTTTGCCGGAAGACTCTCTC-30, reverse 50-GGGTGCTCTGGTAATTT
TCCTTA-30; NT4/5 forward 50-TGAGCTGGCATATGCGAC, reverse 50-CAGCGC
GTCTCGAAGAAGT-30; PDGF forward 50-GCAAGACCAGGACGGTCATTT,
reverse 50-GGCACTTGACACTGCTCGT-30; and NGF-b forward 50-GCACTA
CACCCATCAAGTTCA-30, reverse 50-TCCTGAGTCATGCTCACAAGT-30. The
resulting PCR products were placed in a QIAxcel apparatus (Qiagen) and
analyzed using the QIAxcel gel analysis software (QIAxcel Biocalculator).
Statistical analysis. Student’s t-test for independent samples was used to
detect significant differences between sham and MSC-grafted or MSC-grafted and
control fimbria for each case, using IBM SPSS Statistic v19.0.0 software (Armonk,
NY, USA).
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